|
Activity | Compound | Clinical trial |
|
Inhibitors of Tau hyperphosphorylation: glycogen synthase kinase 3 inhibitors (GSK3β) | (i) Tideglusib (ii) NP031112 (iii) Sodium selenite (VEL015) | (i) NCT01350362 phase II (ii) NCT00948259 (iii) ACTRN12611001200976 phase II |
Inhibitors of Tau aggregation | RemberTM, TRx 0237 | NCT01626391, NCT01689233, NCT01689246 and NCT01626378 |
Microtubule stabilizers | (i) Paclitaxel (ii) Epothilone D (iii) TPI 287 (taxane) | (i) Clinical trial 2013 (interrupted) (ii) NCT01966666 |
Tau-specific immunotherapy | AADvac1 vaccine | NCT01850238 and NCT02031198 phase I trial (2013) |
|
Anticholinesterase inhibitors | (i) Donepezil, rivastigmine, galantamine, (ii) Ladostigil (TV3326) | |
|
PrPC–mGluR5–Fyn signaling | (i) Masitinib (ii) Saracatinib (AZD0530) | (i) NCT00976118 (ii) NCT01864655 and NCT02167256 |
|
5-HT6 receptor blockage | Lu-AE-58054 (SGS-518), PF-05212365 (SAM-531), SUVN-502, AVN-322, PRX-07034 | Different phases of clinical trials |
|
Antidiabetic drugs | (i) Rosiglitazone and pioglitazone (ii) Intranasal insulin (Humulin R U-100) (iii) Amylin and pramlintide (amylin analog) | (i) NCT00550420, NCT00348140 phase III (ii) NCT01767909 (iii) NCT01429623 and NCT01354691 phase II |
|
Cdk5 inhibitors | Roscovitine and flavopiridol | |
|